These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15625544)

  • 1. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
    Johnston LJ; Brown J; Shizuru JA; Stockerl-Goldstein KE; Stuart MJ; Blume KG; Negrin RS; Chao NJ
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):47-55. PubMed ID: 15625544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
    Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
    Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of budesonide mouthwash on oral chronic graft versus host disease.
    Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
    Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.
    Couriel DR; Saliba R; Escalón MP; Hsu Y; Ghosh S; Ippoliti C; Hicks K; Donato M; Giralt S; Khouri IF; Hosing C; de Lima MJ; Andersson B; Neumann J; Champlin R
    Br J Haematol; 2005 Aug; 130(3):409-17. PubMed ID: 16042691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies.
    Fervenza FC; Fitzpatrick PM; Mertz J; Erickson SB; Liggett S; Popham S; Wochos DN; Synhavsky A; Hippler S; Larson TS; Bagniewski SM; Velosa JA;
    Nephrol Dial Transplant; 2004 May; 19(5):1288-92. PubMed ID: 15102967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
    Platzbecker U; von Bonin M; Goekkurt E; Radke J; Binder M; Kiani A; Stoehlmacher J; Schetelig J; Thiede C; Ehninger G; Bornhäuser M
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):101-8. PubMed ID: 19135948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
    Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.
    Kobayashi K; Kami M; Murashige N; Kusumi E; Kishi Y; Hamaki T; Hori A; Matsumura T; Yuji K; Masuo S; Mori S; Miyakoshi S; Tanosaki R; Mitamura T; Takaue Y; Taniguchi S;
    Br J Haematol; 2005 Jun; 129(6):795-802. PubMed ID: 15953007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can we help patients with refractory chronic graft versus host disease- single centre experience.
    Rzepecki P; Barzal J; Sarosiek T; Oborska S; Szczylik C
    Neoplasma; 2007; 54(5):431-6. PubMed ID: 17688373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
    Wolff D; Gerbitz A; Ayuk F; Kiani A; Hildebrandt GC; Vogelsang GB; Elad S; Lawitschka A; Socie G; Pavletic SZ; Holler E; Greinix H
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1611-28. PubMed ID: 20601036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
    Claxton DF; Ehmann C; Rybka W
    Br J Haematol; 2005 Jul; 130(2):256-64. PubMed ID: 16029454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.
    Andree H; Hilgendorf I; Leithaeuser M; Junghanss C; Holzhueter S; Loddenkemper C; Steiner B; Freund M; Wolff D
    Bone Marrow Transplant; 2008 Oct; 42(8):541-6. PubMed ID: 18641680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.